Prevalence of HPV 16/18 genotypes and histopathologic follow-up outcomes in women with negative cytology and positive high-risk HPV test results.
Management of human papillomavirus (HPV)-positive/cytology-negative patients has represented a special challenge ever since the introduction in 2003 of routine cytology and HPV cotesting of women 30 years and older. Since the U.S. Food and Drug Administration's approval in 2009 of an HPV 16/18 genotyping test, guidelines have included an HPV 16/18 genotyping triage option for identifying high-risk HPV-positive/cytology-negative patients who would benefit from immediate colposcopic referral. A retrospective database search was conducted to identify patients with HPV-positive/cytology-negative results between May 1, 2010 and June 30, 2013 in an academic women's hospital practice in which clinical staff consented to routine HPV 16/18 genotyping triage testing of women 30 years and older with HPV-positive/cytology-negative results. Of 824 cytology-negative/HPV-positive cases with valid HPV 16/18 genotyping results, positive results were obtained in 101 (12.3%). HPV 16 was detected most frequently (9.1%), followed by HPV 18 (2.4%) and both 16 and 18 (0.7%). Histopathologic follow-up results were documented over an average of 3.5 months (range 0.5 to 22.5) in 51 patients with HPV-positive/cytology-negative/HPV 16/18-positive results; cervical intraepithelial neoplasia 2/3 biopsy diagnoses were reported in 4 of 51 (7.8%). Previously we reported cervical intraepithelial neoplasia 2+ diagnoses in 2.4% of 849 high-risk HPV-positive/cytology-negative patients followed for almost 2 years without HPV 16/18 genotype testing. These initial routine clinical practice findings are consistent with data from both long-term research studies and recent shorter term clinical trials indicating enhanced risk stratification of HPV-positive/cytology negative patients with HPV 16/18 genotype testing. This is the first report of the application of this option in a routine clinical practice setting.